- Home
- MPLN vs FDMT Comparison
MPLN vs FDMT Comparison
Compare MPLN & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPLN
- FDMT
- Stock Information
- Founded
- MPLN 1980
- FDMT 2013
- Country
- MPLN United States
- FDMT United States
- Employees
- MPLN N/A
- FDMT N/A
- Industry
- MPLN Business Services
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- MPLN Consumer Discretionary
- FDMT Health Care
- Exchange
- MPLN Nasdaq
- FDMT Nasdaq
- Market Cap
- MPLN 229.8M
- FDMT 268.6M
- IPO Year
- MPLN N/A
- FDMT 2020
- Fundamental
- Price
- MPLN $19.54
- FDMT $6.05
- Analyst Decision
- MPLN Hold
- FDMT Buy
- Analyst Count
- MPLN 2
- FDMT 11
- Target Price
- MPLN $26.25
- FDMT $41.70
- AVG Volume (30 Days)
- MPLN 164.0K
- FDMT 702.2K
- Earning Date
- MPLN 02-25-2025
- FDMT 02-27-2025
- Dividend Yield
- MPLN N/A
- FDMT N/A
- EPS Growth
- MPLN N/A
- FDMT N/A
- EPS
- MPLN N/A
- FDMT N/A
- Revenue
- MPLN $942,614,000.00
- FDMT $17,000.00
- Revenue This Year
- MPLN N/A
- FDMT N/A
- Revenue Next Year
- MPLN $1.16
- FDMT $159.36
- P/E Ratio
- MPLN N/A
- FDMT N/A
- Revenue Growth
- MPLN N/A
- FDMT N/A
- 52 Week Low
- MPLN $4.80
- FDMT $4.43
- 52 Week High
- MPLN $53.60
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- MPLN 70.87
- FDMT 58.20
- Support Level
- MPLN $15.25
- FDMT $5.29
- Resistance Level
- MPLN $20.47
- FDMT $5.65
- Average True Range (ATR)
- MPLN 1.70
- FDMT 0.37
- MACD
- MPLN 0.18
- FDMT 0.22
- Stochastic Oscillator
- MPLN 85.32
- FDMT 94.61
About MPLN MultiPlan Corporation
MultiPlan Corp is a provider of data analytics and technology-enabled solutions designed to bring affordability, efficiency, and fairness to the U.S. healthcare industry. The company interprets clients' needs and customizes solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.